Clinical trials.

RVS of CNY participates in industry-sponsored and investigator-initiated clinical trials in retinal disease. Below are our currently enrolling and upcoming studies. To inquire about eligibility, ask your referring physician or contact our research coordinator. We keep this page as up to date as possible, but trial status can change quickly — please call to confirm before referring or planning a visit.

Currently enrolling

Updated as frequently as possible

TRL-01

4D-4FRONTWet AMD · Treatment-Naïve

4D-150 gene therapy versus standard Eylea injections in treatment-naïve wet AMD. Two-year study with three loading doses and a 20-week tapering steroid drop.

Enrolling

TRL-02

AquariusWet AMD

Ixo-vec gene therapy versus Eylea every 8 weeks for wet AMD. Open to both treatment-naïve and previously treated patients. Five-year study with a 27-week tapering steroid drop.

Enrolling

TRL-03

CapriDiabetic Macular Edema

EYP Insert versus Eylea for diabetic macular edema. Open to naïve and previously treated patients with Type 1 or Type 2 diabetes. 88-week study.

Enrolling

TRL-04

SiennaGeographic Atrophy

Subcutaneous pozelimab plus cemdisiran versus cemdisiran alone versus placebo for geographic atrophy secondary to AMD. Two-year study.

Enrolling

TRL-05

Galaxy ONLGeographic Atrophy · Non-Subfoveal

ONL 1204 versus Izervay versus sham for non-subfoveal geographic atrophy. 72-week study.

Enrolling

TRL-06

Astellas Real-WorldGeographic Atrophy · Izervay

Real-world observational study of Izervay (avacincaptad pegol) for geographic atrophy. Five-year study with consent and questionnaires prior to injection.

Enrolling

Upcoming

We are also planning trials in geographic atrophy, wet AMD, retinal vein occlusion, and diabetic macular edema, with new studies expected to open over the coming months.

How to inquire about a trial

If you are a patient, the best path is to ask your referring eye doctor whether enrollment may be appropriate, or to bring it up at your next visit with us. If you are a physician interested in referring for a specific trial, please contact our research coordinator at (315) 445-8166.

Regulatory & oversight

Institutional Biosafety Committee oversight: Advarra IBC meeting minutes (PDF).